

**IND SWIFT LABORATORIES LTD.**

**Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160 101  
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st, Dec 2016  
CIN L24232CH1995PLC015553**

(Rs. In Lacs)

Particulars	Quarter Ended	Quarter Ended	Quarter	Nine Month	Nine Month	Year Ended
	31.12.2016	30.09.2016	Ended 31.12.2015	Ended Dec 2016	Ended Dec 2015	31.03.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income from Operations:</b>						
(a) Net Sales/Incomes from Operations	16710.15	16641.15	15041.37	50858.53	48102.57	63874.40
(b) Other Operating Income	741.43	370.57	397.34	1504.24	1043.52	1418.47
<b>Total Net Sales / Operating Income</b>	<b>17451.58</b>	<b>17011.72</b>	<b>15438.71</b>	<b>52362.76</b>	<b>49146.09</b>	<b>65292.86</b>
<b>EXPENSES:</b>						
a Cost of Materials Consumed	9020.35	8120.95	7853.14	25924.45	26008.78	33753.87
b.Purchase of stock inTrade	68.51	127.75	221.95	284.99	393.25	582.63
c.( Increase) /decrease in FG,WIP & stock in trade	233.70	896.01	33.26	1747.44	1019.13	91.08
d. Staff cost	1785.04	1783.18	1624.38	5358.18	4625.93	6482.41
e. Depreciation	2195.18	2201.95	2140.08	6585.53	6372.36	8474.88
f. Other expenditure	3038.03	2931.37	2890.75	9581.06	8696.43	12122.69
<b>TOTAL EXPENSES</b>	<b>16340.81</b>	<b>16061.21</b>	<b>14763.57</b>	<b>49481.65</b>	<b>47115.89</b>	<b>61507.55</b>
Profit(loss) from Operations before Other Income, finance cost & Exceptional Items	1110.77	950.50	675.14	2881.11	2030.20	3785.32
Misc Income	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit(Loss) before Interest &amp; Exceptional Items</b>	<b>1110.77</b>	<b>950.50</b>	<b>675.14</b>	<b>2881.11</b>	<b>2030.20</b>	<b>3785.32</b>
Interest	2149.81	2258.46	2447.90	6820.74	7640.77	10800.55
Previous year income/expenses	17.49	269.72	7.27	301.41	36.96	52.90
Forex Fluctuation Expenditure/(income )	(154.50)	(134.79)	(48.98)	(222.87)	(714.49)	(159.77)
<b>Profit(Loss) after Interest but before Exceptional Items</b>	<b>(902.03)</b>	<b>(1442.88)</b>	<b>(1731.04)</b>	<b>(4018.17)</b>	<b>(4933.03)</b>	<b>(6908.36)</b>
Exceptional Items	0.00	0.00	0.00	0.00	0.00	1405.26
<b>Profit (+)/ Loss (-) from Ordinary Activities before tax</b>	<b>(902.03)</b>	<b>(1442.88)</b>	<b>(1731.04)</b>	<b>(4018.17)</b>	<b>(4933.03)</b>	<b>(8313.62)</b>
Provision for defferred Tax	0.00	0.00	0.00	0.00	0.00	(2427.51)
<b>Net Profit / (Loss) for the period after Tax</b>	<b>(902.03)</b>	<b>(1442.88)</b>	<b>(1731.04)</b>	<b>(4018.17)</b>	<b>(4933.03)</b>	<b>(5886.11)</b>
Provision for dividend on Equity Shares						
Provision for Equity dividend Tax						
Transfer to General reserve						
<b>Retained Profit / (Loss)</b>	<b>(902.03)</b>	<b>(1442.88)</b>	<b>(1731.04)</b>	<b>(4018.17)</b>	<b>(4933.03)</b>	<b>(5886.11)</b>
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	4473.96	4148.25	4096.32	4096.32	4096.32	4096.32
Reserve excluding revaluation reserves						18887.80
EPS (of Rs. 10/- each) (Not annualised)						
Basic	(2.02)	(3.23)	(4.23)	(8.98)	(12.04)	(14.37)
Diluted	(2.02)	(3.23)	(4.23)	(8.98)	(12.04)	(14.37)

**Notes: -**

- Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 30.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. Few of the FD holders have however approached the courts for repayments of their fixed deposits.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th , February 2017
- The previous period figures have been re-grouped and re-arranged wherever necessary.
- The Company is exclusively in the Pharmaceutical Business segment.

For Ind-Swift Laboratories Ltd.

*NR Munjal*

NR Munjal  
Vice Chairman cum  
Managing Director

Place : Chandigarh  
Date : 14.02.2017